A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

Ruxolitinib (RUX)-based combinations may provide benefit for patients with myelofibrosis (MF). In this open-label, nonrandomized, prospective phase 2 study, patients with MF initially received RUX twice per day continuously in 28-day cycles for the first 3 cycles. Azacitidine (AZA) 25 mg/m(2) (days...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Masarova, Lucia, Verstovsek, Srdan, Hidalgo-Lopez, Juliana E., Pemmaraju, Naveen, Bose, Prithviraj, Estrov, Zeev, Jabbour, Elias J., Ravandi-Kashani, Farhad, Takahashi, Koichi, Cortes, Jorge E., Ning, Jing, Ohanian, Maro, Alvarado, Yesid, Zhou, Lingsha, Pierce, Sherry, Gergis, Romany, Patel, Keyur P., Luthra, Rajyalakshmi, Kadia, Tapan M., DiNardo, Courtney D., Borthakur, Gautam, Bhalla, Kapil, Garcia-Manero, Guillermo, Bueso-Ramos, Carlos E., Kantarjian, Hagop M., Daver, Naval
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6265645/
https://ncbi.nlm.nih.gov/pubmed/30185431
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-04-846626
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados